TMC278-TiDP6-C215: A Clinical Trial in Treatment Naive HIV-subjects Patients Comparing TMC278 to Efavirenz in Combination With 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors

NCT00543725 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

680

Enrollment

INDUSTRY

Sponsor class

Conditions

HIV Infections
HIV-1

Interventions

DRUG: TMC278
DRUG: efavirenz

Sponsor

Tibotec Pharmaceuticals, Ireland